Cortellis Life Sciences data now on WRDS

Wednesday, November 15, 2017

CORTELLIS LIFE SCIENCES HEALTHCARE DATA — Enable impactful research with the world's most comprehensive suite of life sciences data

Academic subscribers -- Access Cortellis sample data here >>

For subscription information, please contact

• Key competitive intelligence information on 67,700+ drugs, 53,300+ deals, 152,600+ companies and 158+ diseases
• Research backgrounds for diseases with profiles of key targets and supporting bibliographic references

• Access the 99 structures per patent from Derwent World Patents Index for 6+ million patents in over 3.1 million patent families to identify which companies are active in a particular therapeutic area
• Data is sourced from WIPO (PCT), Wila (EP, US), Derwent Innovation (INPADOC), SPCs, Electronic Orange Book and patent office websites

• Access regulatory reference documents, summaries of procedures and reports from 200+ sources and 80 regulatory authorities around the world to track changes and compare requirements and procedures across regulatory authorities.

• View 4,500+ diseases, procedures and symptoms
• Research the Incidence and Prevalence Database (IPD) to analyze the world’s epidemiology data, including incidence, prevalence, morbidity, mortality, etc.

• Gain insightful news coverage of the biopharma sector.
• Analyze therapeutic product development from early to late stage — accessing corporate financings, both public and private.

• Access summaries of more than 2,200,000 selected journal articles from 1964 to date
• Clinical Trial Protocols from more than 30 registries and Trial outcomes from journals, conferences, press releases, etc.

Research with Cortellis Life Sciences Data

Phase II and phase III failures: 2013–2015, Nature Reviews Drug Discovery, Richard K Harrison (Clarivate Analytics)

Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications, Nature Reviews Drug Discovery, H. Shih, X. Zhang and A. Aronov (Vertex Pharmaceuticals